2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 7, 2017

2:30PM-4:00PM: Abstract Number: 2807

Can the Automated Neuropsychological Assessment Metrics (ANAM) Predict Cognitive Impairment Compared to a Comprehensive Neuropsychological Battery in Patients with Lupus?

Systemic Lupus Erythematosus – Clinical Aspects and Treatment IV: Neuropsychiatric Disease and Health Economics

2:30PM-4:00PM: Abstract Number: 2765

Centre of Pressure Characteristics during Walking in Individuals with and without First Metatarsophalangeal Joint Osteoarthritis

ARHP Rehabilitation Science

2:30PM-4:00PM: Abstract Number: 2795

Comparison of Switching from the Originator Rituximab to the Biosimilar Rituximab GP2013 or Re‑Treatment with the Originator Rituximab in Patients with Active Rheumatoid Arthritis: Safety and Immunogenicity Results from a Multicenter, Randomized, Double-Blind Study

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy III: Biosimilars Therapy

2:30PM-4:00PM: Abstract Number: 2775

Critical Role of Neutrophil Extracellular Traps (NETs) in Patients with Behcet’s Disease

Innate Immunity and Rheumatic Disease

2:30PM-4:00PM: Abstract Number: 2789

Deficiency of the Novel Rheumatoid Arthritis (RA) Risk Gene, LBH, Induces Replication Stress in RA Fibroblast-like Synoviocytes (FLS) and Exacerbates Arthritis Severity

Rheumatoid Arthritis – Human Etiology and Pathogenesis I

2:30PM-4:00PM: Abstract Number: 2811

Economic Evaluation of Damage Accrual in a Nationwide Canadian SLE Cohort

Systemic Lupus Erythematosus – Clinical Aspects and Treatment IV: Neuropsychiatric Disease and Health Economics

2:30PM-4:00PM: Abstract Number: 2768

Effects of a Home-Based Telephone-Supported Physical Activity Program on Physical Function Among Older Adults with Chronic Low Back Pain

ARHP Rehabilitation Science

2:30PM-4:00PM: Abstract Number: 2801

Effects of Anti-IL17 Blockade with Secukinumab on Systemic and Local Immune Responses: A Mechanism-of-Action Study in Peripheral Spondyloarthritis

Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment III

2:30PM-4:00PM: Abstract Number: 2799

Efficacy, Safety and Immunogenicity in Randomized, Double-Blind (DB) and Open-Label Extension (OLE) Studies Comparing FKB327, an Adalimumab Biosimilar, with the Adalimumab Reference Product (Humira®; RP) in Patients (pts) with Active Rheumatoid Arthritis (RA)

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy III: Biosimilars Therapy

2:30PM-4:00PM: Abstract Number: 2797

Etanercept Biosimilar GP2015 Has Equivalent Efficacy and Safety to Etanercept Originator in Patients with Moderate to Severe Rheumatoid Arthritis: The Phase 3 Equira Study

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy III: Biosimilars Therapy

2:30PM-4:00PM: Abstract Number: 2817

Expression Patterns of Interferon Induced Genes in Newborns Exposed to Ro/SSA Autoantibodies in Utero

Systemic Lupus Erythematosus – Human Etiology and Pathogenesis I

2:30PM-4:00PM: Abstract Number: 2777

Factors Associated with Readiness for Adopting Osteoporosis Treatment Change

Patient Outcomes, Preferences, and Attitudes II

2:30PM-4:00PM: Abstract Number: 2818

Gene Expression Analysis Demonstrates That Multiple Type 1 Interferons Are Involved in Lupus Pathogenesis

Systemic Lupus Erythematosus – Human Etiology and Pathogenesis I

2:30PM-4:00PM: Abstract Number: 2764

Gene Expression Profile in Monocytes of Antiphospholipid Syndrome Patients Reveals Novel Altered Genes and Pathways Involved in the Pathophysiology of the Disease

Antiphospholipid Syndrome

2:30PM-4:00PM: Abstract Number: 2812

Healthcare Resource Utilization and Costs in Patients with Systemic Lupus Erythematosus before and after Initiating Treatment with Intravenous Belimumab: A US Claims Database Analysis

Systemic Lupus Erythematosus – Clinical Aspects and Treatment IV: Neuropsychiatric Disease and Health Economics

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].